<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               14 CLINICAL STUDIES<BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.1 HER2 Positive Metastatic Breast Cancer <BR>                     <BR>                        The efficacy and safety of TYKERB in combination with capecitabine in breast cancer were evaluated in a randomized, Phase 3 trial. Patients eligible for enrollment had HER2 (ErbB2) overexpressing (IHC 3+ or IHC 2+ confirmed by FISH), locally advanced or metastatic breast cancer, progressing after prior treatment that included anthracyclines, taxanes, and trastuzumab. <BR>                        Patients were randomized to receive either TYKERB 1,250 mg once daily (continuously) plus capecitabine 2,000 mg/m2/day on Days 1-14 every 21 days, or to receive capecitabine alone at a dose of 2,500 mg/m2/day on Days 1-14 every 21 days. The endpoint was time to progression (TTP). TTP was defined as time from randomization to tumor progression or death related to breast cancer. Based on the results of a pre-specified interim analysis, further enrollment was discontinued. Three hundred and ninety-nine (399) patients were enrolled in this study. The median age was 53 years and 14% were older than 65 years. Ninety-one percent (91%) were Caucasian. Ninety-seven percent (97%) had stage IV breast cancer, 48% were estrogen receptor+ (ER+) or progesterone receptor+ (PR+), and 95% were ErbB2 IHC 3+ or IHC 2+ with FISH confirmation. Approximately 95% of patients had prior treatment with anthracyclines, taxanes, and trastuzumab.<BR>                        Efficacy analyses 4 months after the interim analysis are presented in Table 5, Figure 1, and Figure 2.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="_RefIDF6EFBBC7671342A6802BDAC34383387A"><BR>                           <caption>Table 5. Efficacy Results </caption><BR>                           <col width="17%"/><BR>                           <col width="28%"/><BR>                           <col width="22%"/><BR>                           <col width="28%"/><BR>                           <col width="22%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td rowspan="3" styleCode="Lrule Toprule "/><BR>                                 <td align="center" colspan="2" styleCode="Botrule Lrule Toprule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Independent </content><BR>                                       <content styleCode="bold">Assessment</content><BR>                                       <sup>a</sup><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Investigator Assessment</content><BR>                                    </paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Lrule Botrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">TYKERB 1,250&#160;mg/day + </content><BR>                                       <content styleCode="bold">Capecitabine</content><BR>                                       <content styleCode="bold"> 2,000&#160;mg/m<sup>2</sup>/day</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Lrule Botrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Capecitabine</content><BR>                                       <content styleCode="bold"> 2,500&#160;mg/m<sup>2</sup>/day</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">TYKERB 1,250&#160;mg/day + </content><BR>                                       <content styleCode="bold">Capecitabine</content><BR>                                       <content styleCode="bold"> 2,000&#160;mg/m<sup>2</sup>/day</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Capecitabine</content><BR>                                       <content styleCode="bold"> 2,500&#160;mg/m<sup>2</sup>/day</content><BR>                                    </paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Lrule Botrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">(N&#160;=&#160;198)</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Lrule Botrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">(N&#160;=&#160;201)</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">(N&#160;=&#160;198)</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">(N&#160;=&#160;201)</content><BR>                                    </paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Number of TTP events</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Lrule Botrule "><BR>                                    <paragraph>82</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Lrule Botrule "><BR>                                    <paragraph>102</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>121</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>126</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Median TTP, weeks</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Lrule "><BR>                                    <paragraph>27.1</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Lrule "><BR>                                    <paragraph>18.6</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Lrule "><BR>                                    <paragraph>23.9</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Lrule "><BR>                                    <paragraph>18.3</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule "><BR>                                    <paragraph>(25<sup>th</sup>, 75<sup>th</sup>, Percentile), weeks</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>(17.4, 49.4)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Lrule Botrule "><BR>                                    <paragraph>(9.1, 36.9)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>(12.0, 44.0)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>(6.9, 35.7)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Hazard Ratio </content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" colspan="2" styleCode="Rrule Lrule "><BR>                                    <paragraph>0.57</paragraph><BR>                                 </td><BR>                                 <td align="center" colspan="2" styleCode="Rrule Lrule "><BR>                                    <paragraph>0.72</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule "><BR>                                    <paragraph>(95% CI)</paragraph><BR>                                 </td><BR>                                 <td align="center" colspan="2" styleCode="Rrule Lrule "><BR>                                    <paragraph>(0.43, 0.77)</paragraph><BR>                                 </td><BR>                                 <td align="center" colspan="2" styleCode="Rrule Lrule "><BR>                                    <paragraph>(0.56, 0.92)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule "><BR>                                    <paragraph><BR>                                       <content styleCode="italics">P</content> value</paragraph><BR>                                 </td><BR>                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>0.00013</paragraph><BR>                                 </td><BR>                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>0.00762</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Response Rate (%)</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Lrule "><BR>                                    <paragraph>23.7</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Lrule "><BR>                                    <paragraph>13.9</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Lrule "><BR>                                    <paragraph>31.8</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>17.4</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule "><BR>                                    <paragraph>(95% CI) </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Botrule Lrule "><BR>                                    <paragraph>(18.0, 30.3)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Botrule Lrule "><BR>                                    <paragraph>(9.5, 19.5)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule Lrule "><BR>                                    <paragraph>(25.4, 38.8)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>(12.4, 23.4)</paragraph><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>TTP = Time to progression.<BR>                        <BR>                           a The time from last tumor assessment to the data cut-off date was >100 days in approximately 30% of patients in the independent assessment. The pre-specified assessment interval was 42 or 84 days.<BR>                        <BR>                           Figure 1. Kaplan-Meier Estimates for Independent Review Panel-evaluated Time to Progression <BR>                        <BR>                        <BR>                           Figure 2. Kaplan-Meier Estimates for Investigator Assessment Time to Progression <BR>                        <BR>                        At the time of above efficacy analysis, the overall survival data were not mature (32% events). However, based on the TTP results, the study was unblinded and patients receiving capecitabine alone were allowed to cross over to TYKERB plus capecitabine treatment. The survival data were followed for an additional 2 years to be mature and the analysis is summarized in Table 6.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="_RefID8CA263F892E5413CA0B3016C03F4869D"><BR>                           <caption>Table 6: Overall Survival Data </caption><BR>                           <col width="31%"/><BR>                           <col width="54%"/><BR>                           <col width="31%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule Toprule "/><BR>                                 <td align="center" styleCode="Botrule Lrule Toprule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">TYKERB 1,250&#160;mg/day + </content><BR>                                       <content styleCode="bold">Capecitabine</content><BR>                                       <content styleCode="bold"> 2,000&#160;mg/m<sup>2</sup>/day </content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">(N = 207)</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Capecitabine</content><BR>                                       <content styleCode="bold"> 2,500&#160;mg/m<sup>2</sup>/day</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">(N = 201)</content><BR>                                    </paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Overall Survival</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td styleCode="Lrule Botrule "/><BR>                                 <td styleCode="Rrule Lrule Botrule "/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule "><BR>                                    <paragraph> Died </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Lrule Botrule "><BR>                                    <paragraph>76%</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>82%</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule "><BR>                                    <paragraph> Median Overall Survival (weeks)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Lrule Botrule "><BR>                                    <paragraph>75.0</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>65.9</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule "><BR>                                    <paragraph> Hazard ratio, 95% CI</paragraph><BR>                                    <paragraph> (<content styleCode="italics">P</content> value)</paragraph><BR>                                 </td><BR>                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule "><BR>                                    <paragraph>0.89 (0.71, 1.10)</paragraph><BR>                                    <paragraph>0.276</paragraph><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>CI = confidence interval<BR>                     <BR>                     <BR>                     <BR>                        <BR>                           Figure 1. Kaplan-Meier Estimates for Independent Review Panel-evaluated Time to Progression<BR>                           <BR>                              <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           Figure 2. Kaplan-Meier Estimates for Investigator Assessment Time to Progression<BR>                           <BR>                              <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.2 Hormone Receptor Positive, HER2 Positive Metastatic Breast Cancer<BR>                     <BR>                        The efficacy and safety of TYKERB in combination with letrozole were evaluated in a double-blind, placebo-controlled, multi-center study. A total of 1,286 postmenopausal women with hormone receptor positive (ER positive and/or PgR positive) metastatic breast cancer, who had not received prior therapy for metastatic disease, were randomly assigned to receive either TYKERB (1,500 mg once daily) plus letrozole (2.5 mg once daily) (n = 642) or letrozole (2.5 mg once daily) alone (n = 644). Of all patients randomized to treatment, 219 (17%) patients had tumors overexpressing the HER2 receptor, defined as fluorescence in situ hybridization (FISH) (≥2 or 3+ immunohistochemistry (IHC). There were 952 (74%) patients who were HER2 negative and 115 (9%) patients did not have their HER2 receptor status confirmed. The primary objective was to evaluate and compare progression-free survival (PFS) in the HER2 positive population. Progression-free survival was defined as the interval of time between date of randomization and the earlier date of first documented sign of disease progression or death due to any cause.<BR>                        The baseline demographic and disease characteristics were balanced between the two treatment arms. The median age was 63 years and 45% were 65 years of age or older. Eighty-four percent (84%) of the patients were White. Approximately 50% of the HER2 positive population had prior adjuvant/neo-adjuvant chemotherapy and 56% had prior hormonal therapy. Only 2 patients had prior trastuzumab.<BR>                        In the HER2 positive subgroup (n = 219), the addition of TYKERB to letrozole resulted in an improvement in PFS. In the HER2 negative subgroup, there was no improvement in PFS of the TYKERB plus letrozole combination compared to the letrozole plus placebo. Overall response rate (ORR) was also improved with the TYKERB plus letrozole combination therapy. The overall survival (OS) data were not mature. Efficacy analyses for the hormone receptor positive, HER2 positive and HER2 negative subgroups are presented in Table 7 and Figure 3. <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="_RefID546446AF596F4B24A5F4A561C735662C"><BR>                           <caption>Table 7. Efficacy Results </caption><BR>                           <col width="18%"/><BR>                           <col width="31%"/><BR>                           <col width="18%"/><BR>                           <col width="31%"/><BR>                           <col width="18%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td rowspan="3" styleCode="Botrule Lrule Toprule "/><BR>                                 <td align="center" colspan="2" styleCode="Botrule Lrule Toprule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">HER2(+) Population</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">HER2(-) Population</content><BR>                                    </paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Lrule Botrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">TYKERB 1500&#160;mg/day + </content><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                       <content styleCode="bold"> 2.5&#160;mg/day</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Lrule Botrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                       <content styleCode="bold"> 2.5&#160;mg/day</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Lrule Botrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">TYKERB 1500&#160;mg/day + </content><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                       <content styleCode="bold"> 2.5&#160;mg/day</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                       <content styleCode="bold"> 2.5&#160;mg/day</content><BR>                                    </paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Lrule Botrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">(N&#160;=&#160;111)</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Lrule Botrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">(N&#160;=&#160;108)</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Lrule Botrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">(N&#160;=&#160;478)</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">(N&#160;=&#160;474)</content><BR>                                    </paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Median </content><BR>                                       <content styleCode="bold">PFS<sup>a</sup><BR>                                       </content><BR>                                       <content styleCode="bold">, weeks</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">(95% CI)</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Lrule Botrule "><BR>                                    <paragraph>35.4</paragraph><BR>                                    <paragraph>(24.1, 39.4)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Lrule Botrule "><BR>                                    <paragraph>13.0</paragraph><BR>                                    <paragraph>(12.0, 23.7)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Lrule Botrule "><BR>                                    <paragraph>59.7</paragraph><BR>                                    <paragraph>(48.6, 69.7)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>58.3</paragraph><BR>                                    <paragraph>(47.9, 62.0)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Hazard Ratio (95% CI)</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold"><BR>                                          <content styleCode="italics">P</content> value</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" colspan="2" styleCode="Lrule Botrule "><BR>                                    <paragraph>0.71 (0.53, 0.96)</paragraph><BR>                                    <paragraph>0.019</paragraph><BR>                                 </td><BR>                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>0.90 (0.77, 1.05)</paragraph><BR>                                    <paragraph>0.188</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Response Rate (%)</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">(95% CI)</content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Botrule Lrule "><BR>                                    <paragraph>27.9</paragraph><BR>                                    <paragraph>(19.8, 37.2)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Botrule Lrule "><BR>                                    <paragraph>14.8</paragraph><BR>                                    <paragraph>(8.7, 22.9)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Botrule Lrule "><BR>                                    <paragraph>32.6</paragraph><BR>                                    <paragraph>(28.4, 37.0)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule Lrule "><BR>                                    <paragraph>31.6</paragraph><BR>                                    <paragraph>(27.5, 36.0)</paragraph><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>PFS = progression-free survival; CI = confidence interval.<BR>                        <BR>                           a Kaplan-Meier estimate.<BR>                        <BR>                           Figure 3. Kaplan-Meier Estimates for Progression-Free Survival for the HER2 Positive Population <BR>                        <BR>                     <BR>                     <BR>                     <BR>                        <BR>                           Figure 3. Kaplan-Meier Estimates for Progression-Free Survival for the HER2 Positive Population<BR>                           <BR>                              <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>